. DEREK SEE TAG MANAGER URL???
#

Reg. CF

SoLá Therapy

Offering By Uroshape, LLC

About Documents
2%
Funded - $1000
Time Left - 168 days
Target - $50,000
Max. Raise - $524,000

Share

Project Overview


SoLá Therapy

1 in 10 women suffer from debilitating pelvic pain, including endometriosis and IC. Before SoLá Therapy, millions of women were without hope. There was no pathway to rapid pain relief.

SoLá Therapy Headlines

  • The First Major Improvement In Decades For The Treatment Of Chronic Pelvic Pain, Including Endometriosis And IC.
  • Only Legally-Marketed Medical Device In This Multi-Billion-Dollar Pelvic Pain Market.
  • Better And Faster Than The Standard Of Care, Physical Therapy.
  • Supported By More Real-World Data Than Any Other Treatment For Chronic Pelvic Pain.
  • Lead Investors Include The Creator Or Sirius XM And CEO Of United Therapeutics
  • More Than 2,500 Procedures Performed Since Q4 Of 2019
  • Company President, Dr. Barbara Levy, Served As The Vice President For Health Policy At The American College Of Obstetricians And Gynecologists (ACOG) From 2012 To 2019 And Served As A Two-Term Chair Of The American Medical Association RUC Committee. 
  • Company Chief Science Officer, Dr. Georgine Lamvu, Is Chairwoman Of The International Pelvic Pain Society.

 

Uroshape is the first medical device company to address this debilitating disorder that affects more women than asthma or diabetes. 1 in 10 women suffer from pelvic pain. These women have pain with intercourse, sitting, standing, exercise, urination, and/or bowel movements. Common diagnoses include endometriosis, interstitial cystitis, pelvic congestion, pelvic neuralgia, and pelvic floor dysfunction. Since our launch in late 2019, we have partnered with gynecologists and urologists across the U.S. who have performed over 2,500 treatments. UroShape’s SoLá Therapy offers rapid pain relief to women who previously had little hope. Regardless of diagnosis, 85% of women with chronic pelvic pain share a common pain generator: pelvic muscle spasm. Most women treated with the SoLá Therapy Near-Infrared Laser achieve maximum improvement in less than three weeks. The SoLá Therapy Laser is painless, non-destructive, and treatments are only 2-4 minutes in length. Unlike medications that cause side effects such as hot flashes, headaches, bone loss, and fatigue, SoLá side effects are minimal. In contrast to most devices and medications that rely solely on biased clinical trials to demonstrate effectiveness, SoLá Therapy combines clinical trials with real-world evidence. The SoLá Therapy Touch Screen gathers information on the results of every treatment for every patient while protecting patient privacy. Because no patient’s experience is excluded, our data reflects real-world results.  This provides potential patients an authentic picture of how SoLá Pelvic Therapy may help them conquer pelvic pain. 

SoLá Therapy’s team is composed of renowned doctors specializing in pelvic medicine, including our Chief Science Officer Dr. Georgine Lamvu, the Chairwoman of the International Pelvic Pain Society, and business leaders in healthcare technology. With the introduction of SoLá Therapy, the team has entered an estimated 10 billion dollar domestic market and a worldwide market expected to exceed 20 billion dollars. The company’s financial milestones will be exceeded if it treats only 1% of American women suffering from pelvic pain.

Although 1 in 10 women suffer from debilitating pelvic pain, there has not been any salient solution on the market that has proven to be as effective as SoLá Therapy. All other medications and treatments, with the exception of vaginal physical therapy, have demonstrated very limited effectiveness. Vaginal physical therapy, performed by a small number of specialty physical therapists, is often painful. Vaginal PT is typically part of 8-10 one-hour-long treatments performed over 8-10 weeks. The SoLá Therapy Laser is painless, treatments last 2-4 minutes, and the entire treatment series is typically completed in just 2-4 weeks. SoLá Therapy is simple to perform and highly reproducible. Our market size is impressive. Treatment can be delivered at the offices of over 40,000 gynecologists, and 14,000 urologists. Although our financial projections consider only female patients, the male pelvic pain market is nearly as big, equally needing a solution. We are now planning to enter the male market later this year.

SoLá Therapy works by delivering therapeutic Near-Infrared laser energy directly into the pelvis. This process is known as photobiomodulation. Some scientists call this the photosynthesis of the human cell. Near-infrared light reacts with the microscopic organs inside each cell, releasing toxins and stimulating energy production. One of the key by-products of photobiomodulation is nitric oxide. Nitric oxide is a powerful relaxer of both painful spastic pelvic muscles and the muscles of blood vessel walls. Blood vessel relaxation improves circulation, delivering oxygen to oxygen-deprived tissues. Unlike commonly used medical lasers, the SoLá Therapy Laser generates a wavelength of energy that is non-destructive and therefore remarkably safe.

 

SoLá Therapy’s business model allows physicians to escape the burden of buying expensive equipment and earn profits on their first day using the system. Physicians enter into a 36-month, $700 per month, subscription agreement for the use of the SoLá Therapy Laser, maintenance, and updates. Physicians pay this monthly fee to a third-party lender who pays Uroshape (that’s us) the full value of the subscription agreement upfront. Each time a physician enrolls a new patient for treatment by entering information into the laser’s touch screen, the physician’s credit card is charged for the sterile disposable laser wands used for that patient.

Physicians charge the patient a cash fee for treatment. A typical three-week treatment series ranges from $1,500 to $2,500. Secondary to high insurance deductibles and the limited effectiveness of other treatment options, SoLá Therapy is typically the most cost-effective option.

SoLá Therapy’s cash-pay business model has been validated by both patients and physicians across the U.S. Additionally; our company is on a pathway to insurance reimbursement. This initiative is being led by our President, Dr. Barbara Levy, who was a two-term chair of the American Medical Association (AMA) Resource Based Relative Value Scale Update Committee (RUC). We have started a patient advocacy program to submit insurance claims, are applying for a billing code (CPT code), and are well underway to accumulating the necessary data support CMS and private payor insurance determinations. Although reimbursement is expected, our success is not predicated on it.

Because SoLá Therapy is the only legally marketed medical device available to treat the majority of women with Chronic Pelvic Pain, it has a significant potential for growth. The only salient treatment alternative is Vaginal Physical Therapy, which is often painful and lengthy.

SoLá Therapy has been successfully commercialized as a cash pay procedure with clinical validation and is generating annually recurring revenue. We are on a pathway to healthcare insurance reimbursement. The company is expected to achieve a topline revenue of $53 million in four to five years.

The company’s total addressable U.S. target market is represented by 10 million women suffering from chronic pelvic pain with muscle spasms, equating to a $10 billion domestic market. The worldwide market opportunity is estimated to be over $20 billion. Topline revenue and EBITDA are projected to lead to a rewarding exit by 2024-2025. As our company has a validated cash-pay business, an exit is not beholden to reimbursement.

 

Company Pitch Deck

Download SoLá Therapy Pitch Deck

Use of Proceeds

49% - Sales, General, Advertising
23% - Cost of Goods
19% - Pathway to reimbursement w/ Clinic Evidence Growth
5% - Liabilities
4% - R & D

Ownership Structure & Rights of Securities

MINIMUM INVESTMENT

$300


 

INVESTMENT DETAILS

 

Safe Note: Your investment converts to common shares at the time of the next equity event or sale of the company.

Discount applied at the time of conversion to common stock:

Investments up to $999 receive a 5% discount on common stock.

Investments of $1,000 to $9,999 receive a 10% discount on common stock.

Investments of $10,000 to $14,999 receive a 12% discount on common stock.

Investments of $15,000 or greater receive a 15% discount on common stock.

Conversion price is guaranteed to be equal to or less than the share price at the valuation cap.


 

PRE MONEY VALUATION: $15.5 Million

Max Raise: $500,000


 

VALUATION CAP: $19.5 Million


PERKS:

Do you know someone with pelvic pain? Invest $1000 and receive a $500 SoLá Therapy gift certificate.  Investors of greater than $5,000 will receive a gift certificate* for a complete SoLá Therapy Treatment Series. That’s a $2,500 value.

Are you a licensed physician that would like to offer SoLá Therapy? Investors of $25,000 or more will receive a gift certificate* for an 18-month subscription to use the SoLá Therapy Laser. That’s a $12,500 value!

Are you an active SoLá Therapy Provider? Investors of $25,000 or more will receive a gift certificate* for 18 patient treatment kits. That’s a $12,500 value.

*Gift Certificates are redeemable for up to 12 months following your investment.

Risks & Disclosures

A private placement investment involves significant risk. You should not invest any funds in this offering unless you can afford to lose your entire investment.

In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document.

The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature.

These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

An investment in the Company involves a high degree of risk. You should carefully consider the risks described above and those below before deciding to purchase any securities in this offering. If any of these risks actually occurs, our business, financial condition or results of operations may suffer. As a result, you could lose part or all of your investment.

Risks Related to the Company

  • Our business, results of operations, and financial condition may be impacted by the recent coronavirus (COVID-19) outbreak.

    With respect to the ongoing and evolving coronavirus (COVID-19) outbreak, which was designated as a pandemic by the World Health Organization on March 11, 2020, the outbreak has caused substantial disruption in international and U.S. economies and markets. The outbreak has potential to have an adverse impact on the fintech industry and, if repercussions of the outbreak are prolonged, could have a significant adverse impact on our business, which could be material. Our management cannot at this point estimate the impact of the outbreak on its business and no provision for this outbreak is reflected in the accompanying financial statements.

  • We are an early stage company and have not yet generated any profits.

    The company was formed in 2010, however, it only began distributing its SoLa Therapy laser and accessories in 2019.  Accordingly, the company has a limited history upon which an evaluation of its performance and future prospects can be made. The company’s current and proposed operations are subject to all the business risks associated with new enterprises. These include likely fluctuations in operating results as the company reacts to developments in its market, managing its growth and the entry of competitors into the market. The company has incurred a net loss and has had limited revenues generated since inception. There is no assurance that the company will be profitable in the next three years or generate sufficient revenues to pay dividends to the holders of the shares.    

  • Any valuation at this stage is difficult to assess.

    The valuation for the offering was established by the company. Unlike listed companies that are valued publicly through market-driven stock prices, the valuation of private companies, especially startups, is difficult to assess and you may risk overpaying for your investment.

  • The company operates in a highly regulated industry.

    We are subject to extensive regulation and failure to comply with such regulation could have an adverse effect on our business. In addition, changes in the regulatory environment of the pain market could adversely affect the company’s ability to further penetrate the pain market.

  • The company is reliant on one main type of product.

    The company is reliant on the sales of one type of product, the SoLa Therapy laser and accessories. The company’s revenues are therefore dependent upon the market for a solution to chronic pelvic pain, or CPP. In addition, the company relies heavily on third parties such as OBGYN’s and physical therapists to purchase and use the SoLa Therapy laser and accessories. 

  • The company may face substantial competition, which may result in others discovering, developing, or commercializing products more successfully than the company does.

    In general, the CPP industry is subject to intense competition and rapid and significant technological change. Although currently, the company is the first entrant into its category, there may be many potential competitors, including major drug companies, specialized biotechnology firms, academic institutions, government agencies, and private and public research institutions. Many of these competitors have significantly greater financial and technical resources than us, and superior experience and expertise in research and development, preclinical testing, design and implementation of clinical trials, regulatory processes and approval for products, production and manufacturing, and sales and marketing of approved products. Smaller or early-stage companies and research institutions may also prove to be significant competitors, particularly if they have collaborative arrangements with larger and more established biotechnology companies. The company will also face competition from these parties in recruiting and retaining qualified scientific and management personnel. In addition, our technologies and products also may be rendered obsolete or noncompetitive as a result of products introduced by our competitors.

  • SoLa Therapy laser will require market acceptance to be successful. Failure to gain market acceptance would impact the company’s revenues and may materially impair its ability to continue our business.

    The commercial success of the company’s products will depend on, among other things, their acceptance by physicians, patients, third-party payers such as health insurance companies, and other members of the medical community as a therapeutic and cost-effective alternative to competing products and treatments. There can be no assurance that these parties will adopt the use of our device. Market acceptance of, and demand for, any product that we may develop and commercialize will depend on many factors, both within and outside of our control. Payers may view new products or products that have only recently been launched or with limited clinical data available, as investigational, unproven, or experimental, and on that basis may deny coverage of procedures involving use of the company’s products. If SoLa Therapy laser fails to gain market acceptance, the company may be unable to earn sufficient revenue to continue its business.

  • We depend on key personnel and face challenges recruiting needed personnel.

    Our future success depends on the efforts of a small number of key personnel. In addition, due to our limited financial resources and the specialized expertise required, we may not be able to recruit the individuals needed for our business needs. There can be no assurance that we will be successful in attracting and retaining the personnel we require to operate and be innovative.

  • If the company cannot raise sufficient funds it will not succeed. 

    The company is offering Common Units in the amount of up to $12,000,000 in this offering, and may close on any investments that are made. Even if the maximum amount is raised, the company is likely to need additional funds in the future in order to grow, and if it cannot raise those funds for whatever reason, including reasons relating to the company itself or to the broader economy, it may not survive. If the company manages to raise only the minimum amount of funds sought, it will have to find other sources of funding.

  • If the company cannot protect, maintain and, if necessary, enforce its intellectual property rights, its ability to develop and commercialize products will be adversely impacted.

    The company’s success, in large part, depends on its ability to protect and maintain the proprietary nature of its technology. We must prosecute and maintain our existing patents and obtain new patents. Some of the company’s proprietary information may not be patentable, and there can be no assurance that others will not utilize similar or superior solutions to compete with the company. The company cannot guarantee that it will develop proprietary products that are patentable, and that, if issued, any patent will give a competitive advantage or that such patent will not be challenged by third parties. The process of obtaining patents can be time consuming with no certainty of success, as a patent may not issue or may not have sufficient scope or strength to protect the intellectual property it was intended to protect. The company cannot assure you that its means of protecting its proprietary rights will suffice or that others will not independently develop competitive technology or design around patents or other intellectual property rights issued to the company. Even if a patent is issued, it does not guarantee that it is valid or enforceable. Any patents that the company or our licensors have obtained or obtain in the future may be challenged, invalidated, or unenforceable. If necessary, the company will initiate actions to protect its intellectual property, which can be costly and time consuming.

  • The company will depend upon strategic relationships to develop, exploit, and manufacture its products. If these relationships are not successful, the company may not be able to capitalize on the market potential of these products.

    The near and long-term viability of the company’s products will depend, in part, on its ability to successfully establish new strategic collaborations with hospitals, insurance companies, manufacturers and government agencies. Establishing strategic collaborations is difficult and time-consuming. Potential collaborators may reject collaborations based upon their assessment of the company’s financial, regulatory, or intellectual property position. If the company fails to establish a sufficient number of collaborations on acceptable terms, it may not be able to commercialize its products or generate sufficient revenue to fund further research and development efforts.

  • The company’s financials were prepared on a “going concern” basis.

    The company’s financial statements were prepared on a “going concern” basis. Certain matters indicate there may be substantial doubt about the company's ability to continue as a going concern. The company sustained losses of $1,867,865 and $877,900 for the years ended December 31, 2019 and 2018, respectively, and has an accumulated deficit of $569,694 as of December 31, 2019. 2020 financials are being reviewed. The company’s ability to continue operations is dependent upon its ability to generate sufficient cash flows from operations to meet our obligations, which the company has not been able to accomplish to date, and/or to obtain additional capital financing. 

Risks Related to the Company's Securities and this Offering

  • We intend to the proceeds from the offering for unspecified working capital.

    This means that we have ultimate discretion to use this portion of the proceeds as we see fit and have chosen not to set forth any specific uses for you to evaluate. The net proceeds from this offering will be used for the purposes, which our management deems to be in our best interests in order to address changed circumstances or opportunities. As a result of the foregoing, our success will be substantially dependent upon our discretion and judgment with respect to application and allocation of the net proceeds of this offering. We may choose to use the proceeds in a manner that you do not agree with and you will have no recourse. A use of proceeds that does not further our business and goals could harm our company and its operations and ultimately cause you to lose all or a portion of your investment.

  • Our securities are restricted securities and cannot be transferred freely. Our Company's securities are not listed on any exchange or on the over-the-counter market and are very illiquid. Our securities cannot be transferred without complying with all applicable restrictions on transfer.

    An investment in our Company is a long-term commitment. There are substantial restrictions on the transferability of our securities. The offering has not been registered under the Securities Act and the Common Unit is being offered in reliance upon the exemption from registration under the Securities Act under Rule 506(c) and the provisions of Regulation D promulgated thereunder. Sales of the Company securities hereunder will be made only to “accredited investors” as such term is defined in Rule 501(a) of Regulation D under the Securities Act and the Company shall take reasonable steps to verify that the Investors are “accredited investors.”

    Since the offering will not be registered under the Securities Act, in reliance on an exemption for private offerings under Rule 506(c), the securities issued in the offering will be “restricted securities” as that term is defined in Rule 144 under the Securities Act and, accordingly, under Rule 144 as currently in effect, the Securities must be held for the time period required by Rule 144 (or indefinitely if Investor is deemed an “affiliate” within the meaning of such rule) unless the securities are subsequently registered under the Securities Act and qualified under any other applicable securities law or exemptions from such registration and qualification are available.

    In addition, there is no public market for our securities and such a public market may never develop. The securities are not registered under the Securities Act and, therefore, cannot be resold unless they are later registered or unless an exemption from registration is available. Rule 144 under the Securities Act permits limited public resale of unregistered securities if certain conditions are satisfied. These conditions include, among other things, (i) the resale occurring not less than six months after the holder has acquired and made full payment for the security, (ii) the availability of certain public information about the issuer, and (iii) in the case of an affiliate, or of a non-affiliate who has held the security less than one year, (a) the sale being made through a broker in an unsolicited “broker's transaction” or in a transaction directly with a market maker and (b) the amount of securities being sold in any three-month period not exceeding certain specified limitations. The information required for Rule 144 to apply is not currently available and may not be available in the future.

  • Investing in private placements like this offering involve significant risks not present in investments in public offerings.

    Investing in private placements involves a high degree of risk. Securities sold through private placements are typically not publicly traded and, therefore, are less liquid. Additionally, investors may receive restricted securities that may be subject to holding period requirements. Companies seeking private placement investments tend to be in earlier stages of development and have not yet been fully tested in the public marketplace. Investing in private placements requires high risk tolerance, low liquidity concerns, and long-term commitments. Investors must be able to afford to lose their entire investment. Investment products are not FDIC insured, may lose value, and there is no bank guarantee.

  • We are not subject to Sarbanes-Oxley regulations and lack the financial controls and safeguards required of public companies.

    We do not have the internal infrastructure necessary, and are not required, to complete an attestation about our financial controls that would be required under Section 404 of the Sarbanes-Oxley Act of 2002. There can be no assurance that there are no significant deficiencies or material weaknesses in the quality of our financial controls. We expect to incur additional expenses and diversion of management's time if and when it becomes necessary to perform the system and process evaluation, testing and remediation required in order to comply with the management certification and auditor attestation requirements.

  • Neither the offering nor the securities have been registered under federal or state securities laws, leading to an absence of certain regulation applicable to us.

    No governmental agency has reviewed or passed upon this offering, our company or any Securities of our company. We also have relied on exemptions from securities registration requirements under applicable state securities laws. Investors, therefore, will not receive any of the benefits that such registration would otherwise provide. Prospective investors must therefore assess the adequacy of disclosure and the fairness of the terms of this offering on their own or in conjunction with their personal advisors.

  • No Guarantee of Return on Investment

    There is no assurance that an investor will realize a return on its investment or that it will not lose its entire investment. For this reason, each investor should read the subscription agreement and this risk factor disclosure carefully and should consult with its own attorney and business advisor prior to making any investment decision.

  • A majority of our company is owned by a small number of owners.

    Prior to the offering our officers, directors and those of our members who own ten percent or more of our securities collectively own directly or indirectly approximately 65% of our company. Subject to any fiduciary duties owed to our other owners or investors under Florida law in the case of our officers and directors, these members may be able to exercise significant influence over matters requiring owner approval, including the election of directors or managers and approval of significant company transactions, and will have significant control over our management and policies. These control persons may have interests that are different from yours. For example, they may support proposals and actions with which you may disagree. The concentration of ownership could delay or prevent a change in control of our company or otherwise discourage a potential acquirer from attempting to obtain control of the Company, which in turn could reduce the price potential investors are willing to pay for our company. In addition, this owner could use his voting influence to maintain the Company's existing management, delay or prevent changes in control of our company, or support or reject other management and board proposals that are subject to owner approval.

  • Your ownership of the shares will be subject to dilution.

    If we conduct subsequent offerings of securities, issue shares pursuant to a compensation or distribution reinvestment plan or otherwise issues additional shares, investors who purchase securities in this offering who do not participate in those other membership interest issuances will experience dilution in their percentage ownership of our company's outstanding shares. Furthermore, shareholders may experience a dilution in the value of their underlying shares depending on the terms and pricing of any future share issuances (including the underlying shares being sold in this offering) and the value of the our assets at the time of issuance.

  • The securities will be equity interests in our company and will not constitute indebtedness.

    The securities will rank junior to all existing and future indebtedness and other non-equity claims on our company with respect to assets available to satisfy claims on the Company, including in a liquidation of our company. Additionally, unlike indebtedness, for which principal and interest would customarily be payable on specified due dates, there will be no specified payments of dividends with respect to the securities and dividends are payable only if, when and as authorized and declared by us and depend on, among other matters, our historical and projected results of operations, liquidity, cash flows, capital levels, financial condition, debt service requirements and other cash needs, financing covenants, applicable state law, federal and state regulatory prohibitions and other restrictions and any other factors our board of directors deems relevant at the time. In addition, there is no limit on the amount of debt or other obligations we may incur in the future. Accordingly, we may incur substantial amounts of additional debt and other obligations that will rank senior to the securities, which are the most junior securities of our company.

  • There can be no assurance that we will ever provide liquidity to investors through either a sale of our company or a registration of the securities.

    There can be no assurance that any form of merger, combination, or sale of our company will take place, or that any merger, combination, or sale would provide liquidity for investors. Furthermore, we may be unable to register the securities for resale by investors for legal, commercial, regulatory, market-related or other reasons. In the event that we are unable to effect a registration, investors could be unable to sell their securities unless an exemption from registration is available.

  • The offering price in this offering may not represent the value of our securities.

    The price of the securities being sold in this offering has been determined based on a number of factors and does not necessarily bear any relationship to our book value, assets, operating results or any other established criteria of value. Prices for our securities may not be indicative of the fair market value of our securities now or in the future.

View our
Offering Documents

Gallery

Meet the SoLá Therapy team

Chief Executive Officer
RALPH ZIPPER, MD, FPMRS

- Over 22 years of both industry and clinical experience in the field of pelvic medicine. - Dr. Zipper has taken multiple products from conception to commercialization. - Vast experience in IP development, product development, labeling, regulatory affairs, evidence generation, and DTC marketing. - Fellowship trained in gynecology and obstetrics at the Johns Hopkins Hospital. - Dr. Zipper has trained over 1,000 surgeons and hundreds of sales representatives.

President
DR. BARBARA LEVY

- Vice President for Health Policy at the American College of Obstetricians and Gynecologists (AGOG) from 2012 to 2019. - Two terms as chair of the American Medical Association Resource Based Relative Value Scale Update Committee (RUC) - Currently sits on the American Medical Association (AMA) Current Procedural Terminology (CPT) editorial panel

Chief Operating Officer
KEVIN RICHARDSON, MBA

- Over 20 years of global commercial and operational leadership experience in healthcare technology - Former CEO of the Americas for Sirtex Medical where he grew NA sales from $30MM to over $140MM - Medical device experience with Boston Scientific and St. Jude Medical

Chief Scientific Officer
GEORGINE LAMVU, MD, MPH

- Chairwoman of the International Pelvic Pain Society. - Professor in Obstetrics and Gynecology at the UCF - Director of the Fellowship in Minimally Invasive Surgery at the Orlando VA Medical Center - Author of 56 peer-reviewed publications and multiple textbook chapters on pelvic pain.

Advisors

#
KRISTENE WHITMORE, MD
Philadelphia, PA
  • Professor Surgery/Urology and OB/GYN Drexel University College of Medicine & Reconstructive Surgery, Drexel University College of Medicine
  • Chair Urology and Female Pelvic Medicine & Reconstructive Surgery,
  • Past President American Urogynecology Association
#
STEPHANIE PRENDERGAST, MPT
Los Angeles, CA
  • CEO Pelvic Health & Rehabilitation Centers
  • Past President International Pelvic Pain Society
  • Board Member IPPS
#
NEERAJ KHOLI, MD, MBA
Boston, MA
  • Medical Director, Boston Urogyn
  • Assistant Professor, Ob/Gyn, Harvard Medical School
  • Past Chief Urogynecology Harvard’s Bringham & Women’s Hospital
#
FRANK TU, MD, MPH
Chicago, IL
  • Associate Professor, Ob/Gyn University of Chicago
  • Vice Chair, Quality Northshore Health
  • Past President International Pelvic Pain Society
  • Board Member IPPS
#
MICHAEL HIBNER, MD, PHD
Phoenix, AZ
  • Associate Professor, Ob/Gyn, College of Medicine Phoenix
  • Board Member International Pelvic Pain Society
CHARLES BUTRICK, MD, FPRMS
Kansas City, KS
  • SoLá Therapy Chief Medical Officer
  • Former President of the International Pelvic Pain Society and former President of the International Society of Pelvic Neuromodulation
  • One of the most recognized and key opinion leaders in the area of Chronic Pelvic Pain and Pelvic Medicine

Project FAQs

Ask A Question

Comments